Back to top
more

ADMA Biologics (ADMA)

(Delayed Data from NSDQ)

$20.29 USD

20.29
4,247,997

+0.72 (3.68%)

Updated Oct 4, 2024 04:00 PM ET

After-Market: $20.22 -0.07 (-0.34%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (73 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

BioVie (BIVI) Falls 61% Despite Upbeat Alzheimer's Study Data

by Zacks Equity Research

BioVie (BIVI) stock plunges 61% in spite of positive phase III Alzheimer's Disease study results due to significant study conduct violations and protocol deviations reported by the company.

Acadia (ACAD) Begins Alzheimer's Disease Psychosis Study (Revised)

by Zacks Equity Research

Acadia (ACAD) initiates a phase II study on ACP-204 in the treatment of Alzheimer's disease psychosis, the first among the three studies planned in the phase II/III clinical program of the candidate.

Acadia (ACAD) Begins Alzheimer's Disease Psychosis Study

by Zacks Equity Research

Acadia (ACAD) initiates a phase II study on ACP-204 in the treatment of Alzheimer's disease psychosis, the first among the three studies planned in the phase II/III clinical program of the candidate.

Adma Biologics (ADMA) Is Considered a Good Investment by Brokers: Is That True?

by Zacks Equity Research

The average brokerage recommendation (ABR) for Adma Biologics (ADMA) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?

Is Aurinia Pharmaceuticals (AUPH) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Aurinia Pharmaceuticals (AUPH) and Adma Biologics (ADMA) have performed compared to their sector so far this year.

Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Rhythm Pharmaceuticals, Inc. (RYTM) delivered earnings and revenue surprises of 0% and 2.07%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Is It Worth Investing in Adma Biologics (ADMA) Based on Wall Street's Bullish Views?

by Zacks Equity Research

The average brokerage recommendation (ABR) for Adma Biologics (ADMA) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?

Immatics (IMTX) Moves 23.2% Higher: Will This Strength Last?

by Zacks Equity Research

Immatics (IMTX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Adma Biologics (ADMA) Stock Falls Amid Market Uptick: What Investors Need to Know

by Zacks Equity Research

Adma Biologics (ADMA) closed the most recent trading day at $3.45, moving -1.99% from the previous trading session.

Adma Biologics (ADMA) Ascends While Market Falls: Some Facts to Note

by Zacks Equity Research

Adma Biologics (ADMA) closed at $3.31 in the latest trading session, marking a +0.91% move from the prior day.

Adma Biologics (ADMA) Stock Moves -0.94%: What You Should Know

by Zacks Equity Research

Adma Biologics (ADMA) reachead $3.17 at the closing of the latest trading day, reflecting a -0.94% change compared to its last close.

Adma Biologics (ADMA) Rises As Market Takes a Dip: Key Facts

by Zacks Equity Research

In the most recent trading session, Adma Biologics (ADMA) closed at $3.44, indicating a +1.78% shift from the previous trading day.

Adma Biologics (ADMA) Stock Sinks As Market Gains: Here's Why

by Zacks Equity Research

In the closing of the recent trading day, Adma Biologics (ADMA) stood at $3.34, denoting a -0.3% change from the preceding trading day.

Is Adma Biologics (ADMA) a Buy as Wall Street Analysts Look Optimistic?

by Zacks Equity Research

According to the average brokerage recommendation (ABR), one should invest in Adma Biologics (ADMA). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?

Adma Biologics (ADMA) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

Adma Biologics (ADMA) closed the most recent trading day at $3.59, moving +1.13% from the previous trading session.

Adma Biologics (ADMA) Gains As Market Dips: What You Should Know

by Zacks Equity Research

In the latest trading session, Adma Biologics (ADMA) closed at $3.56, marking a +0.28% move from the previous day.

Adma Biologics (ADMA) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Adma Biologics (ADMA) closed at $3.78 in the latest trading session, marking a -0.26% move from the prior day.

Is It Worth Investing in Adma Biologics (ADMA) Based on Wall Street's Bullish Views?

by Zacks Equity Research

Based on the average brokerage recommendation (ABR), Adma Biologics (ADMA) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?

Atreca (BCEL) Suspends Lead Drug Evaluation, Stock Falls 37%

by Zacks Equity Research

Atreca (BCEL) suspends the development of only pipeline candidate, ATRC-101, in clinical evaluation, as part of its business restructuring efforts and cuts headcount by 40%. The stock falls 37%.

Catalyst (CPRX) Q2 Earnings & Sales Top, 2023 Outlook Raised

by Zacks Equity Research

Catalyst (CPRX) reports better-than-expected second-quarter 2023 results. Management raises full-year 2023 guidance.

Novo Nordisk (NVO) Q2 Earnings and Sales Miss, 2023 View Up

by Zacks Equity Research

Novo Nordisk (NVO) reports weaker-than-expected second-quarter 2023 results, missing both earnings and sales estimates. Management, however, raises 2023 guidance.

Is ADMA Biologics (ADMA) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Adma Biologics (ADMA) and Align Technology (ALGN) have performed compared to their sector so far this year.

Adma Biologics (ADMA) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Adma Biologics (ADMA) delivered earnings and revenue surprises of 0% and 8.43%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zoetis' (ZTS) Q2 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Zoetis (ZTS) reports better-than-expected second-quarter 2023 results, beating both earnings and revenue estimates, primarily driven by the sales of its key dermatology products.

Arvinas, Inc. (ARVN) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Arvinas, Inc. (ARVN) delivered earnings and revenue surprises of 25.15% and 67.98%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?